ERBB2 and breast carcinoma: The current phase III study compared the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of CT-P6 and trastuzumab, administered as both neoadjuvant and adjuvant therapy for patients with operable HER2-positive early breast cancer [10, 11].